Cartéol LP 1%

Quick links

Choose a section

Quick links to important sections

Advertisements

Cartéol LP 1%

Advertisements
Advertisements

Method of action: Ophthalmologicals

Advertisements

Overview of Cartéol LP 1%

Quick Facts

Property Description
Active ingredient Carteolol Hydrochloride
Form Ophthalmic solution (Prolonged-Release)
Pharmacological class Beta-adrenergic receptor blocker
General purpose Reduction of intraocular pressure (IOP)
Origin Synthetic compound

Defining Cartéol LP 1%: An Ophthalmic Beta-Blocker

Cartéol LP 1% is a prescription-only ophthalmic solution primarily classified as a beta-adrenergic receptor blocker, commonly known as a beta-blocker. The medicine is a monotherapy, containing the single active ingredient, Carteolol Hydrochloride, which is a synthetic quinolinone derivative. The drug entity belongs to the therapeutic group of non-selective beta-blockers. As part of this class, the agent helps regulate the body's response to adrenergic stimuli.


What is the Composition and Formulation of Cartéol LP 1%?

The medicine is an aqueous ophthalmic solution with the active substance Carteolol Hydrochloride at a 1% concentration. A differentiating feature is the Prolonged-Release (LP) designation. This indicates an advanced formulation engineered to ensure the active ingredient is released and maintained at a therapeutic level over an extended duration. The unique LP technology distinguishes Cartéol from standard or immediate-release carteolol eye drops, providing a pharmacological benefit focused on sustained delivery. The product is defined by its ocular administration route and its use as a single-agent eye drop.


What is the General Therapeutic Purpose of this Eye Drop?

The general therapeutic purpose of Cartéol LP 1% is to function as a topical ocular hypotensive agent. The core objective of the medicine is the consistent and reliable reduction of intraocular pressure (IOP). The active component achieves this by inhibiting the production of aqueous humor, the fluid continuously generated inside the eye. A typical neutral use scenario involves its application to maintain stable, reduced eye pressure in patients with chronic high IOP.

Regulatory References

  1. FDA Drug Information
Advertisements

What side effects are possible with Cartéol LP 1%?

Cartéol LP 1%: Possible Side Effects and Safety Information

Cartéol LP 1% (Carteolol Ophthalmic Solution) is subject to regulatory classifications concerning potential adverse reactions, which are divided into local ocular effects and systemic effects resulting from absorption, characteristic of a beta-blocker.


Adverse Reaction Scope and Classification

Side effects are categorized by frequency and the body system affected, based on official regulatory documents:

Classification Common Examples (SmPC/FDA)
Very Common Transient ocular irritation (burning, stinging), conjunctival redness, tearing, or edema, primarily occurring upon instillation.
Less Common Headache, blurred vision, dizziness, lightheadedness, or slow/irregular heartbeat (bradycardia).
System-Organ Classes Eye Disorders, Cardiac Disorders, Vascular Disorders, Respiratory Disorders, and Nervous System Disorders are officially listed.

Serious Adverse Reactions and Safety Constraints

The potential for systemic beta-blockade necessitates explicit safety constraints and the documentation of serious adverse reactions:

  • Serious Reactions: Documented systemic risks include Cardiac Failure, severe Bronchospasm (especially in susceptible individuals), Syncope, and the potential for Masking of Acute Hypoglycemia symptoms.
  • Contraindications: Use is strictly contraindicated in individuals with pre-existing conditions susceptible to systemic beta-blockade, such as bronchial asthma, severe chronic obstructive pulmonary disease (COPD), sinus bradycardia, second- or third-degree atrioventricular block, and overt cardiac failure.
  • Population Notes: Safety and efficacy have not been established in pediatric patients. Caution is noted for use during pregnancy (Pregnancy Category C) and by nursing mothers.

This regulatory framework establishes that the medicine’s primary safety concern is the risk of systemic effects, which dictates specific restrictions for susceptible patient groups.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Cartéol LP 1% is associated with the systemic effects of a beta-adrenergic blocking agent due to systemic absorption. The most common manifestations documented in regulatory sources include bradycardia (slow heart rate), hypotension (low blood pressure), bronchospasm, and congestive heart failure (CHF). These expected effects primarily target the cardiovascular and respiratory systems. The regulatory profile notes the potential for severe respiratory reactions and cardiac reactions, which can be life-threatening. The risk of these severe outcomes, including death, is noted to be higher in patients with pre-existing conditions such as Bronchial Asthma or Overt Cardiac Failure.

Immediate medical attention is required if overdosage is suspected or if any severe systemic symptoms of beta-blockade are present. The official guidance explicitly states that the medication must be discontinued at the first sign or symptom of cardiac failure. Management of overdosage is supportive and symptomatic, as no specific antidote is known. Specific pharmacological interventions described for treatment include the cautious use of Atropine or Isoproterenol for symptomatic bradycardia or heart block, Vasopressors for persistent hypotension, and a beta2-stimulating agent for bronchospasm. Diuretics and Digitalis Glycosides are described for the management of CHF.

Advertisements

Therapeutic Uses of Cartéol LP 1%

Therapeutic Indications

Cartéol LP 1% is an ophthalmic solution primarily indicated for the management of ocular hypertension. It is used to lower the internal pressure of the eye in patients who have been diagnosed with conditions that cause elevated intraocular pressure.

Chronic Open-Angle Glaucoma

The primary use of this medication is the long-term treatment of chronic open-angle glaucoma. This condition is characterized by a progressive increase in intraocular pressure which, if left unmanaged, can lead to damage of the optic nerve and subsequent vision loss. Cartéol LP 1% helps to maintain eye pressure within a safer range to help preserve visual function.

Ocular Hypertension

This medication is also prescribed for individuals with ocular hypertension. This refers to a state where the pressure inside the eye is higher than the normal range, but the patient does not yet show clinical signs of glaucoma or optic nerve damage. Lowering this pressure is a preventative measure used to reduce the risk of future glaucomatous damage.

Mechanism of Action and Benefits

Reduction of Intraocular Pressure

As a beta-blocking agent, the active ingredient in Cartéol LP 1% works by reducing the production of aqueous humor, the fluid naturally found within the front part of the eye. By decreasing the rate at which this fluid is produced, the overall pressure within the eye is lowered.

Long-Acting Formulation

The "LP" designation indicates a prolonged-release formulation. This technology is designed to release the active substance gradually, allowing for a sustained effect on intraocular pressure throughout the day. This consistent pressure control is a key benefit in the management of chronic eye conditions.

Regulatory References

  1. FDA DailyMed label for Ocupress (Carteolol)
Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Cartéol LP 1%

This section describes who should and should not use this medicine based solely on governmental regulatory information (e.g., FDA and EMA labeling). The active ingredient is carteolol, a nonselective beta-blocker.

Eligibility Classification Conditions and Populations
Contraindicated (Must NOT Use) Bronchial asthma or history of asthma, severe chronic obstructive pulmonary disease (COPD), sinus bradycardia, second- or third-degree atrioventricular (AV) block, overt cardiac failure, cardiogenic shock, or known hypersensitivity to the drug or any beta-blockers.
Use Not Recommended Pediatric patients (0–18 years): Safety and effectiveness have not been established in this age group.
Use with Caution/Restrictions Patients with non-allergic bronchospasm (e.g., chronic bronchitis, emphysema), diminished pulmonary function, diabetes, hyperthyroidism, myasthenia gravis, or severe peripheral circulatory disturbances. Use during pregnancy is advised only if the benefit justifies the potential risk, and caution is required for nursing mothers as excretion into human milk is unknown, though shown in animal studies.

Eligibility is defined by the absence of severe cardiovascular and respiratory diseases. Individuals with conditions like diabetes must be closely monitored due to the risk of masking symptoms of hypoglycemia.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Cartéol LP 1% (Carteolol Hydrochloride ophthalmic solution) focuses on pharmacodynamic interactions stemming from potential systemic absorption, which may lead to additive effects on the cardiovascular system.


Documented Interaction Categories

Category Description of Official Interaction Pattern
Additive Systemic Beta-Blockade Co-administration with oral beta-adrenergic blocking agents or catecholamine-depleting drugs (e.g., Reserpine) carries a risk of additive effects, such as marked bradycardia (slow heart rate) and hypotension (low blood pressure).
Functional Interference The medication may mask the signs of acute hypoglycemia (low blood sugar), such as a rapid pulse rate, in diabetic patients. The beta-blockade effect may also render patients unresponsive to the usual doses of epinephrine used to treat severe anaphylaxis.
Topical Administration Timing When used concurrently with other topical ophthalmic medicines, the products must be administered at least five to ten minutes apart to prevent the second medication from washing out the first.

Regulatory documentation does not explicitly list pharmacokinetic interactions involving CYP enzymes or transporters. The primary constraints relate to the heightened risk of additive systemic effects with other depressant agents and mandatory administration spacing for co-administered eye drops.

Advertisements

Mechanism of Action

beta-Adrenergic Receptor Modulation

Cartéol LP 1% (carteolol) works at the molecular level by non-selectively blocking beta1 and beta2 adrenergic receptors located on the ciliary body of the eye. This action is classified as an antagonist (blocker) and is characterized by Intrinsic Sympathomimetic Activity (ISA), which affects the sympathetic signaling pathway that normally stimulates fluid production.


Inhibiting Aqueous Humor Production

The receptor blockade mechanism interrupts the neurohormonal signal that stimulates active secretion processes. By inhibiting this sympathetic input, the medication suppresses the rate of aqueous humor production by the ciliary epithelium, which is the clear fluid that fills the anterior chamber.


Physiological Consequence: Reduced IOP

The effective limitation of fluid production by the ciliary body reduces the steady-state volume of aqueous humor within the anterior chamber. This change in fluid dynamics results in a decrease in intraocular pressure (IOP), which is the final physiological consequence of the mechanism.

Advertisements

Dosage and Administration Information

How to Use Cartéol LP 1%: Official Administration Guidelines

Cartéol LP 1% (Carteolol Hydrochloride Ophthalmic Solution, Prolonged-Release) is indicated for topical ocular use as eye drops. Administration involves specific requirements regarding route, frequency, and timing to ensure proper use.

Administration Scope

Instruction Official Guideline
Route of administration Topical Ocular Use
Standard Dosing Schedule Instill one drop in the affected eye(s)
Frequency and Timing Once daily, administered in the morning
Missed Dose Rule If a dose is missed, continue the therapy with the next scheduled dose the following morning.
Pediatric Use Rule Not recommended for children and adolescents aged 0 to 18 years; efficacy and safety are not established in this group.

Resulting Procedural Structure

The correct application of Cartéol LP 1% involves specific procedural steps to maximize efficacy and prevent contamination. Users must ensure the dropper tip does not touch the eye or any surrounding surfaces. After instillation, nasolacrimal occlusion (applying pressure to the inner corner of the eye) or gentle eyelid closure for two minutes is advised to reduce systemic absorption.

When using other topical eye medications, a separation period is required: concomitant eye drops must be administered at least 5 to 15 minutes apart. Patients wearing soft contact lenses are directed to remove the lenses prior to instillation and wait a minimum of 15 minutes before reinserting them.

These instructions define a standardized, once-daily protocol, ensuring adherence to the intended use of the prolonged-release formulation for long-term Intraocular Pressure (IOP) management, which requires regular monitoring by a healthcare professional.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cartéol LP 1%


Evidence for Use in Intraocular Hypertension (OHT)

The research exploring Cartéol LP 1% for Intraocular Hypertension (OHT) primarily relies on Randomized Controlled Trials (RCTs). These short-term studies were used in research exploring how pressure levels change over time. The trials enrolled adults who had consistently high pressure readings inside the eye. The main outcome research examined was the measured Intraocular Pressure (IOP) itself.

Data showed patterns related to changes in the measured IOP following the use of the ophthalmic solution in the observed populations. Despite the data collected, evidence is limited regarding the long-term effects of the specific Prolonged-Release (LP) formulation, meaning that multi-year outcomes are not fully established.


Evidence for Use in Chronic Open-Angle Glaucoma (OAG)

The medicine was evaluated in a broader range of research scenarios for Chronic Open-Angle Glaucoma (OAG). This evidence base includes many RCTs, systematic reviews, and longer-term observational studies involving adults with a confirmed OAG diagnosis. These studies explored whether stable IOP measurements could be maintained, and researchers also monitored outcomes reflecting daily functioning, such as visual field preservation.

Research describes that lower eye pressure measurements were observed in the study populations. One key limitation is that while extensive long-term data exists for the standard (non-LP) Carteolol eye drop, the long-term effectiveness on slowing disease progression has been less extensively characterized specifically for the Prolonged-Release (LP) formulation.


Research Comparing the Prolonged-Release (LP) Formulation

Specific double-masked, parallel-group studies were conducted to examine the unique Prolonged-Release (LP) formulation. The core goal of this research examined was confirming that the specialized LP formulation demonstrated a similar pattern of change in IOP to the standard formulation when used once a day. Data show patterns related to the eye pressure measurements, which were reported as being equivalent between the two formulations during the short follow-up durations.


What is Still Uncertain About Cartéol LP 1% Research

While a significant body of research contributes to the broader evidence landscape, several limitations and uncertainties exist. The sample sizes were modest in some of the comparative studies, and the follow-up durations were limited in these head-to-head trials. There is limited information for long-term outcomes specifically evaluating the relationship between the Prolonged-Release formulation and the rate of glaucoma progression over five or more years, and this information is generally not fully established.

Key Studies & References

  1. FDA DailyMed Label for Carteolol Hydrochloride Ophthalmic Solution, 1% (Ocupress)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Cartéol LP 1% (FAQ)

Q: Why is Cartéol LP 1% sometimes prescribed as a once-daily drop?

A: Cartéol LP 1% is a prolonged-release (LP) formulation of carteolol. This specialized design allows the active ingredient to be released and maintained at a therapeutic level over an extended period. Because of this formulation, the medication is generally administered once daily, typically in the morning, for sustained pressure control, as noted in official product information.

Q: If I miss a dose of Cartéol LP 1%, what is the general recommendation?

A: According to official product information, if a dose is missed, the regulatory guidance is to continue the therapy with the next scheduled dose the following morning. It is important that the missed dose is not doubled to make up for it.

Q: Should I avoid certain over-the-counter medicines while using Cartéol LP 1%?

A: Official information advises caution regarding other medicines, including over-the-counter products, that may have additive effects on the heart or blood pressure. Specifically, concurrent use with other oral beta-blockers or catecholamine-depleting drugs is noted. Regulatory documents also caution that the beta-blockade effect may render epinephrine (adrenaline) less effective than anticipated when used to treat severe allergic reactions.

Q: Is Cartéol LP 1% available in a generic version (Carteolol)?

A: The active ingredient in Cartéol LP 1% is Carteolol Hydrochloride, which is a substance available generically. However, the specific Prolonged-Release (LP) formulation may not have an identical generic counterpart. Information regarding the availability of a generic version can be confirmed through the prescribing healthcare professional or pharmacist.

Q: Are there research studies comparing Cartéol LP 1% to other glaucoma treatments?

A: Official information discusses research comparing the prolonged-release (LP) formulation to the standard, non-LP formulation of carteolol. Regulatory documents do not explicitly detail studies comparing Cartéol LP 1% directly against other different classes of glaucoma medications, such as prostaglandin analogues.

Q: What is the typical long-term success rate of Cartéol LP 1% in managing eye pressure?

A: Studies indicate that the medication is associated with lowered intraocular pressure (IOP) in the short term. However, official regulatory documents state that long-term outcomes for the specific Prolonged-Release (LP) formulation, particularly those evaluating its effectiveness on glaucoma progression over many years, are not yet fully established.

Q: Could using Cartéol LP 1% make my dry eye symptoms worse?

A: The medication is associated with very common side effects such as transient ocular irritation, burning, and tearing upon instillation. While not explicitly listed as worsening dry eye, official reports note less common eye issues like blepharoconjunctivitis or corneal staining. Concerns about pre-existing conditions should be discussed with a healthcare provider.

Q: Is it normal for my eyelid to look a little droopy (ptosis) after using Cartéol LP 1%?

A: Yes, drooping of the upper eyelid, a condition known as ptosis, has been reported as an occasional adverse reaction in clinical studies involving Carteolol Ophthalmic Solution. This is a recognized side effect associated with the use of this medication.

Q: Does Cartéol LP 1% reduce the production of fluid in the eye?

A: Yes, the primary mechanism of action for Cartéol LP 1% is the reduction of aqueous humor production. It achieves this by blocking beta-adrenergic receptors in the ciliary body. This limits the fluid continuously generated inside the eye, thereby helping to lower intraocular pressure, according to regulatory data.

Q: Is it normal to feel a stinging or burning sensation right after using Cartéol LP 1%?

A: Yes, a transient ocular irritation that includes stinging, burning, or tearing is listed as a very common adverse reaction in official product information. This sensation typically occurs right at the moment the drop is instilled into the eye.

Q: Can Cartéol LP 1% cause tiredness or fatigue?

A: Yes, systemic side effects can occur due to the medicine being absorbed by the body. Official reports indicate that asthenia (unusual weakness or lack of energy) and generalized feelings of fatigue have been reported as adverse effects associated with the use of carteolol.

Q: Can Cartéol LP 1% cause increased sensitivity to light (photophobia)?

A: Yes, photophobia, which is an abnormal sensitivity of the eyes to light, has been occasionally reported as an ocular side effect of the medicine.

Q: Is a metallic or altered sense of taste a possible side effect of Cartéol LP 1%?

A: Yes, an altered sense of taste or taste perversion has been reported as an occasional systemic side effect. This sometimes occurs when the eye drops drain through the tear ducts into the back of the throat.

Q: Does Cartéol LP 1% contain any preservatives that might cause irritation?

A: Yes, the formulation of Carteolol Ophthalmic Solution contains the preservative benzalkonium chloride. Any sensitivities to ingredients should be addressed with a healthcare provider.

Q: What precautions should be taken when driving after using Cartéol LP 1% drops?

A: The medicine can sometimes cause temporary side effects such as blurred vision, dizziness, or lightheadedness. Regulatory guidance suggests waiting until vision is clear and any temporary side effects have subsided before driving or operating machinery.

Q: Could Cartéol LP 1% affect the symptoms of an overactive thyroid condition?

A: Yes. Beta-blockers can mask some of the characteristic clinical signs of an overactive thyroid (hyperthyroidism), such as a rapid heart rate (tachycardia). This effect highlights why patients with this condition require careful supervision during treatment.

Q: Is it safe to use Cartéol LP 1% if I have a history of depression?

A: Depression has been reported as a systemic adverse reaction associated with carteolol. Official information indicates that use of this medicine in patients with a history of depression may necessitate closer monitoring.

Q: Does Cartéol LP 1% work by changing the eye's drainage system?

A: No, the official mechanism of action is primarily to decrease aqueous humor production. Regulatory documents indicate that the drug has little to no reported effect on improving the eye's fluid drainage system.

Q: What is the risk of developing a severe allergic reaction to Cartéol LP 1%?

A: Severe allergic reactions, including anaphylaxis, are a known risk associated with the beta-blocker class of medicines. Regulatory documents caution that patients with a history of severe allergic reactions may exhibit greater reactivity to allergens and may experience a diminished response to standard doses of epinephrine if a reaction occurs.

Q: Is Cartéol LP 1% linked to any long-term changes in vision or the eye structure?

A: The medicine is used to manage IOP to help preserve vision. While occasional ocular side effects like blepharoconjunctivitis or abnormal corneal staining have been reported, regulatory documents do not list any definitive long-term structural changes to the eye specifically linked to this medicine.

Q: Are there any reported side effects related to sleep problems or insomnia from Cartéol LP 1%?

A: Yes, difficulty sleeping or insomnia has been reported as an occasional systemic side effect of the medication.

Q: How does the intrinsic sympathomimetic activity (ISA) of carteolol affect its side effect profile?

A: Carteolol possesses Intrinsic Sympathomimetic Activity (ISA), which is a specific property of some beta-blockers. It is theorized that this property may help to reduce the incidence or severity of certain systemic side effects, such as a very slow heart rate (bradycardia), when compared to beta-blockers without ISA.

Q: Do researchers believe Cartéol LP 1% protects the optic nerve directly?

A: Regulatory documents confirm that the medicine's role is to reduce intraocular pressure (IOP), which is a major risk factor for optic nerve damage and vision loss in glaucoma. The documents do not explicitly confirm a mechanism of direct protection or neuroprotection for the optic nerve outside of IOP reduction.

Q: Can Cartéol LP 1% be used in elderly patients with other medical issues?

A: The medicine is frequently used in older adults, but regulatory documents advise that this population should be closely monitored. Elderly patients are more likely to have age-related heart issues, and use in this population requires careful consideration due to the potential for systemic beta-blockade side effects.

Q: Is Cartéol LP 1% used for purposes other than glaucoma and ocular hypertension?

A: The official therapeutic indications for Cartéol LP 1% are limited to the lowering of intraocular pressure in patients with chronic open-angle glaucoma and ocular hypertension.

Q: Has Cartéol LP 1% been studied for use in children with high eye pressure?

A: Regulatory documents state that safety and effectiveness for this medicine have not been established in pediatric patients aged 0 to 18 years, and its use is therefore not recommended in this age group.

Advertisements

How should Cartéol LP 1% be stored and disposed of?

Storage and Disposal Conditions for Cartéol LP 1%

Official regulatory labeling dictates specific conditions to maintain the stability and integrity of Cartéol LP 1% (carteolol hydrochloride ophthalmic solution).


Storage Requirements

Condition Requirement
Temperature Store at room temperature, typically 15 C to 25 C (59 F to 77 F).
Protection The product must be protected from light and kept from freezing.
Container Store in the original container and keep the cap tightly closed.
Safety Keep the medicine out of the reach of children and pets.

Disposal Instructions

Any unused or expired product must not be kept. Patients are directed to consult a pharmacist or healthcare professional for guidance on proper disposal to ensure environmental safety and prevent improper use. Contaminating the dropper tip must be avoided during handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cartéol LP 1% found in:

A-Z Index: